This health education program aims to help patients living with COPD experience better health outcomes and improved quality of life for the duration of their lives.

25, 2024 — A new method of scanning lungs is able to show in real time how air moves in and out of the lungs as people take a breath in patients with asthma, chronic obstructive pulmonary ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Dupilumab vs placebo was linked to improved health-related quality of life and respiratory symptoms in patients with COPD and T2 inflammation.

Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

As the UK endures another harsh winter, plummeting temperatures and a surge in respiratory infections are placing strain on ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Background The diagnosis of interstitial lung disease (ILD) can pose a challenge as the pulmonary function test (PFT) is only ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first starting to issue payouts. Given the strength of its underlying operations, it ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement ... or chronic obstructive pulmonary disease and also have asthma. Do not change or stop your ...